Next-Generation GLP-1 Drugs: What’s in the Pipeline for 2026-2030

Introduction

The current GLP-1 medications, semaglutide and tirzepatide, produce 15 to 21% weight loss in key trials. That number is going to climb. The pipeline of new metabolic drugs includes triple agonists, oral peptide formulations, monthly injectables, and combination products that target weight, muscle preservation, and complications of obesity.

Eli Lilly, Novo Nordisk, Pfizer, Amgen, Roche, AstraZeneca, and several biotechs are all running phase 2 and phase 3 trials in obesity. Some of these drugs will reach the market by 2027 or 2028. Others will fail. The next 5 years will reshape what pharmacologic obesity treatment looks like.

This piece covers the most advanced programs in development, with realistic timelines and what each drug aims to do differently from current options.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is Retatrutide and When Will It Launch?

Retatrutide is Eli Lilly triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously. The phase 2 trial (Jastreboff et al. 2023, NEJM) randomized 338 adults with obesity to retatrutide at five doses or placebo for 48 weeks. The 12 mg dose produced 24.2% weight loss, the highest reported in any obesity trial to that point.

Quick Answer: Retatrutide (Lilly) is a GLP-1/GIP/glucagon triple agonist showing 24.2% weight loss in phase 2

The phase 3 TRIUMPH program includes multiple trials. TRIUMPH-1 is studying retatrutide in obesity without diabetes. TRIUMPH-2 looks at obesity with diabetes. TRIUMPH-3 focuses on obesity with cardiovascular disease. Primary completion dates extend through 2026.

If phase 3 results match phase 2, retatrutide would set a new ceiling for pharmacologic weight loss. FDA approval, assuming a positive submission, would likely come in late 2026 or 2027. The mechanism combines GLP-1 appetite suppression, GIP energy expenditure effects, and glucagon-driven lipolysis and thermogenesis.

What Is CagriSema?

CagriSema is Novo Nordisk combination of semaglutide and cagrilintide, a long-acting amylin analog. Both are once-weekly injectable peptides administered together. Amylin is a hormone co-secreted with insulin that slows gastric emptying and reduces appetite through different brain regions than GLP-1.

The phase 2 trial (Friedrichsen et al. 2023) tested CagriSema versus semaglutide alone, cagrilintide alone, and placebo. CagriSema produced 22.7% weight loss at 32 weeks, compared to about 15.5% for semaglutide alone and 11.5% for cagrilintide alone.

Phase 3 trials are ongoing under the REDEFINE program. REDEFINE-1 in obesity, REDEFINE-2 in obesity with type 2 diabetes, and others target completion in 2025 to 2026. The December 2024 phase 3 readout from REDEFINE-1 showed 22.7% weight loss, consistent with phase 2 but below the 25%+ that some analysts had hoped for. The drug remains in development with expected FDA submission in 2025 and approval potentially in 2026.

What Is Orforglipron?

Orforglipron is Eli Lilly oral non-peptide GLP-1 receptor agonist. Unlike semaglutide and tirzepatide, which are peptides requiring injection, orforglipron is a small molecule that can be taken orally without absorption enhancers.

The phase 2 trial (Wharton et al. 2023, NEJM) tested orforglipron in obesity over 36 weeks. The highest dose produced 14.7% weight loss, comparable to semaglutide injection in shorter trials. Tolerability was similar to other GLP-1 agonists.

The phase 3 ATTAIN program is testing orforglipron in obesity (ATTAIN-1) and diabetes (ATTAIN-2 and beyond). Primary completion was late 2024 to 2025, with FDA submission expected in 2025. If approved, orforglipron would be the first oral GLP-1 that does not require fasting or absorption enhancers like Rybelsus® does.

What Is MariTide?

MariTide (maridebart cafraglutide) is Amgen monthly dosed obesity drug. It combines a GLP-1 agonist with a GIP receptor antagonist, an unusual approach since the established GIP strategy has been agonism (as with tirzepatide).

The phase 2 results were released in late 2024 and showed about 20% weight loss at 52 weeks with monthly dosing. The mechanism of GIP antagonism for weight loss remains debated. The clinical effect was strong despite the theoretical concern that blocking GIP might be the wrong direction.

Phase 3 is launching with anticipated readouts in 2026 to 2027. Monthly dosing would be a major convenience advantage if effectiveness holds up. FDA submission is unlikely before 2027.

What Is Survodutide?

Survodutide is a dual GLP-1/glucagon receptor agonist from Boehringer Ingelheim and Zealand Pharma. Unlike tirzepatide, which uses GIP, survodutide pairs GLP-1 with glucagon agonism. The theoretical advantage is added energy expenditure and lipolysis from glucagon receptor activation.

The phase 2 trial in obesity showed about 19% weight loss at 46 weeks at the highest dose. The drug is also being studied for MASH (metabolic dysfunction-associated steatohepatitis), where it has shown promising effects on liver fat reduction and fibrosis.

Phase 3 trials are running for both obesity and MASH indications. FDA submission would be 2026 or later, with potential approval in 2027 to 2028. Survodutide is one of the strongest non-Lilly, non-Novo programs in the space.

What Is Pemvidutide?

Pemvidutide is Altimmune dual GLP-1/glucagon agonist, similar in concept to survodutide. The phase 2 MOMENTUM trial tested it in obesity and showed 15.6% weight loss at 48 weeks at the highest dose.

The clinical positioning emphasizes preserved lean mass. Phase 2 substudies suggested less muscle loss compared to historical GLP-1 monotherapy data. Whether this advantage holds up in phase 3 with rigorous body composition measurement is uncertain.

Pemvidutide is also being studied in MASH and obstructive sleep apnea. The drug is several years behind retatrutide and CagriSema in development timeline.

What About Oral Peptide Formulations Beyond Rybelsus?

Oral semaglutide (Rybelsus) was approved in 2019. It uses an absorption enhancer (SNAC) to achieve about 1% bioavailability. The 14 mg daily dose is approximately equivalent in effect to weekly 1 mg injection for diabetes outcomes.

Higher-dose Rybelsus (25 mg and 50 mg daily) was studied in the PIONEER PLUS trial for obesity and showed weight loss comparable to injectable semaglutide. FDA submission for obesity indication is pending. Cost and convenience would compete with injection, which already works well at lower doses.

Novo Nordisk and other companies are developing next-generation oral peptide platforms with potentially higher bioavailability. Whether these reach the market in the next 5 years is uncertain.

What Is Bimagrumab?

Bimagrumab is a monoclonal antibody that blocks the activin type II receptor, which controls muscle growth and adipose tissue. The drug was originally developed for muscle wasting conditions and is now being studied combined with GLP-1 medications.

The rationale is that GLP-1 drugs produce some lean mass loss (typically 25 to 30% of total weight loss). Bimagrumab combined with semaglutide could shift the ratio toward more fat loss and less muscle loss. Phase 2 data has been presented showing this effect.

Larger trials are ongoing. If results hold up, bimagrumab plus GLP-1 could become a standard approach for patients concerned about sarcopenic obesity or muscle preservation during rapid weight loss.

What Is the SURMOUNT-OSA Expansion?

Tirzepatide was approved for obstructive sleep apnea in December 2024 based on the SURMOUNT-OSA trials. This was the first FDA approval of a GLP-1 medication specifically for OSA. The drug reduced apnea-hypopnea index by about 50% on top of weight loss effects.

This sets a template for expanded indications based on outcomes trials. Cardiovascular (SELECT for semaglutide), renal (FLOW for semaglutide), heart failure (STEP-HFpEF), and now sleep apnea have all become approved or expected indications.

The expansion of indications matters for insurance coverage and clinical practice. Each new indication adds patient populations who can access the drug under existing approval pathways.

What About Combination Therapies?

Beyond CagriSema and bimagrumab combinations, several other combination approaches are in development. GLP-1 plus amylin, GLP-1 plus FGF21, GLP-1 plus growth hormone secretagogues, and others have been studied or are in early trials.

The conceptual basis for combinations is that obesity is multifactorial and that hitting multiple pathways may produce stronger effects than maximizing any single one. The trade-off is added complexity, cost, and potential side effects.

Combination products will likely be a major theme of the 2027-2030 era of obesity medicine.

How Does This Affect TrimRx and Compounded Options?

TrimRx works with compounded semaglutide and tirzepatide today. As new molecules reach FDA approval and patent expiration, the compounding landscape may evolve. The current focus is on validated, well-studied active ingredients with strong clinical trial support.

A free assessment quiz starts the clinical review. The personalized treatment plan uses current best evidence, which means semaglutide and tirzepatide for most patients. Newer drugs will integrate into clinical practice as approvals and evidence accumulate.

What Is Unlikely to Change?

Some things in obesity medicine are unlikely to change much in the next 5 years. Weight regain after stopping treatment will probably continue, since the underlying metabolic adaptation does not appear to reverse fully with any current pipeline drug.

GI side effects will remain common, since they trace to the same area postrema activation that drives appetite suppression. Newer drugs may have better tolerability profiles but probably will not eliminate the issue entirely.

Cost will remain a major barrier. New drugs typically launch at high prices and only become widely accessible after patent expiration or government negotiation, which can take a decade or more.

Key Takeaway: Maridebart cafraglutide (MariTide) is monthly dosed and showed 20% loss in phase 2

What About Anti-obesity Vaccines or Gene Therapies?

These exist in very early research but are not in any near-term pipeline. The biology of obesity is complex enough that single-target gene or vaccine approaches are unlikely to produce the kind of magnitude weight loss that polypharmacy or multi-receptor agonism is achieving.

This may change in the next decade as understanding of obesity genetics improves. For now, the practical clinical pipeline is dominated by improved peptide drugs and combinations.

How Should Patients Think About the Pipeline?

For patients currently considering or on GLP-1 treatment, the pipeline is mostly relevant for the future, not the present. Semaglutide and tirzepatide are the best-validated options with the most clinical experience. Newer drugs will not be widely available or affordable for years.

Switching from current options to newer drugs as they emerge is reasonable but not always necessary. The 5 to 6 percentage point gap between semaglutide and tirzepatide already exists. Retatrutide might add another 3 to 4 points. The clinical significance for most individual patients will depend on their response to current therapy.

How Does TrimRx Handle the Evolving Landscape?

TrimRx clinicians stay current on emerging evidence and integrate new options as they become appropriate for clinical use. The personalized treatment plan adapts to what is available and effective for each patient.

A free assessment quiz starts the process. The clinical team works with each patient on appropriate dose, titration, and ongoing response monitoring.

What About Emerging Oral Peptide Platforms?

Beyond Rybelsus and orforglipron, several other oral GLP-1 approaches are in development. Pfizer danuglipron, a small molecule GLP-1 agonist, reached phase 2 trials but was discontinued in 2023 due to tolerability issues. Lotiglipron, another Pfizer compound, was also discontinued. The failures point out how difficult oral small molecule GLP-1 development has been.

Other sponsors are pursuing different oral strategies. Ecnoglutide, an oral GLP-1 peptide from Chinese developer Sciwind, is in phase 2 trials. AstraZeneca has an oral program in early development. Roche has acquired Carmot Therapeutics partly for its oral GLP-1 work.

The economics of oral versus injection will play out over the next decade. Oral medications generally have higher adherence but face manufacturing and bioavailability challenges. Injection is well-established with weekly dosing that already supports good adherence.

How Are Obesity Drugs Being Studied for Adolescents?

The pediatric obesity epidemic has driven interest in GLP-1 medications for adolescents. Wegovy® was approved for adolescents 12 and older in December 2022 based on the STEP TEENS trial (Kelly et al. 2022, NEJM). The trial showed 16.1% weight loss at 68 weeks compared to 0.6% in placebo.

Tirzepatide is being studied in adolescents through the SURMOUNT-TEEN trial. Results are expected in 2025 to 2026. If positive, tirzepatide approval for adolescents would expand pediatric obesity treatment options.

The pediatric use of these medications raises questions about long-term safety, growth, and psychosocial impact. Most experts support careful selection of adolescent patients with significant obesity and comorbidities. Routine adolescent obesity treatment with GLP-1 drugs is not currently the standard.

What About Pregnancy and Reproductive Considerations?

GLP-1 medications are contraindicated in pregnancy. The drugs have not been tested in pregnancy, and animal studies have shown some adverse effects. Patients planning pregnancy should discontinue 2 months before conception based on label recommendations.

Anecdotal reports of unplanned pregnancies among women taking GLP-1 medications have raised interest in reproductive effects. Some patients have reported restored fertility after years of difficulty conceiving, possibly related to weight loss-induced improvements in PCOS or other reproductive hormone disorders.

Post-partum and during breastfeeding, GLP-1 medications are generally not recommended. Studies are limited, and the long-term effects of any infant exposure through breast milk are unknown. Patients should discuss timing of treatment resumption with their clinicians.

How Do Payers Think About the Pipeline?

Insurers and payers face significant cost pressure from existing GLP-1 medications. The pipeline could increase costs further or, with newer agents reaching the market, eventually create more competition and pricing pressure.

Most payers want to see real-world outcomes data, not just trial results. Studies showing actual reductions in downstream medical costs are particularly valuable. SELECT cardiovascular outcomes have helped justify GLP-1 coverage for higher-risk populations.

Manufacturers are negotiating with payers on outcomes-based contracts, value-based pricing, and other arrangements. The cost negotiations affect what patients can access and at what out-of-pocket cost.

What About Combination Products?

Beyond the agonist combinations like CagriSema, fixed-dose combinations of GLP-1 medications with other obesity drugs are being explored. GLP-1 plus phentermine, GLP-1 plus naltrexone-bupropion, and other combinations are in various stages of development.

The logic is that different mechanisms may produce additive effects without overlapping side effects. The execution challenges include managing drug interactions, identifying the right doses, and demonstrating clinical benefit beyond either component alone.

Whether combination products reach FDA approval depends on whether they show meaningful advantages. Single-pill convenience matters for adherence, but the regulatory bar is real efficacy improvement.

What About Long-acting Injectables Beyond Monthly?

Beyond MariTide monthly dosing, longer-acting injectable formulations are in early development. Quarterly, twice-yearly, and annual depot formulations have been explored for GLP-1 medications.

The technical challenge is delivering enough drug in a single injection to last weeks or months while maintaining tolerability. Long-acting injectable formulations for other peptide drugs exist, including monthly GnRH analogs and six-month depot leuprolide.

For GLP-1 medications, the trade-off includes dose adjustment flexibility. Patients who experience side effects on a quarterly depot cannot rapidly reduce drug levels. Weekly dosing allows pause and resume in ways that long-acting depots cannot.

How Will Obesity Pharmacotherapy Integrate with Digital Health?

The next generation of obesity treatment will likely combine pharmacotherapy with digital tools. Continuous glucose monitors, food tracking apps, activity monitors, and AI coaching are all being integrated with medication-based treatment.

Data from these tools can inform dose adjustments, identify side effect patterns, and support behavioral change. The combination may produce better outcomes than medication alone.

Telehealth platforms like TrimRx are in a strong position to integrate digital tools because the technology infrastructure is already in place. Future treatment platforms will likely include more integrated digital coaching alongside medication management.

What About Extreme Obesity Treatment?

For patients with BMI over 50 or 60, current GLP-1 medications produce meaningful but often incomplete results. The pipeline includes drugs being studied specifically in extreme obesity populations.

Triple agonists and combination therapies may produce stronger effects in extreme obesity than monotherapy. The SURMOUNT and STEP trials included patients with high BMIs and showed effect, but the absolute weight loss may be insufficient for some severe cases.

Surgery remains the most effective intervention for extreme obesity. The combination of surgery with pharmacotherapy is increasingly used for patients who need maximum weight loss.

Bottom line: Survodutide is a dual GLP-1/glucagon agonist with MASH and obesity programs

FAQ

When Will Retatrutide Be Available?

Phase 3 trials are ongoing with primary completion dates in 2025-2026. FDA approval, if all goes well, could come in 2026 or 2027.

Is CagriSema Better Than Semaglutide Alone?

Phase 2 and phase 3 data show somewhat greater weight loss (about 22.7% vs 15 to 16%). Whether the advantage justifies the more complex regimen depends on patient context.

Will Oral GLP-1 Drugs Replace Injection?

For some patients, yes. Convenience favors oral. Cost and dose flexibility may favor injection for others. Both will likely coexist.

What Is the Difference Between GLP-1 Monoagonists and Dual or Triple Agonists?

Monoagonists like semaglutide activate only GLP-1. Dual agonists like tirzepatide add GIP. Triple agonists like retatrutide add glucagon. Each adds receptors that contribute to weight loss.

Will Newer Drugs Preserve More Muscle?

Some emerging combinations like bimagrumab plus GLP-1 specifically aim at this. Whether the advantage is clinically meaningful awaits larger trials.

Should I Wait for Newer Drugs?

For most patients, no. Current GLP-1 treatments are highly effective. Waiting years for incremental improvements means missing the benefit of treatment now.

Will the Pipeline Make Current Drugs Obsolete?

Not quickly. Semaglutide and tirzepatide will remain widely used for years as newer drugs slowly enter clinical practice and face price and access barriers.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.